MISSISSAUGA, ON, Aug. 24,
2022 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical
technologies company, will release its Q3 Fiscal 2022 financial
results on Monday, August
29th, 2022, before markets open. A conference
call and webcast to discuss the financial results will be held on
Monday, August 29th, 2022,
at 9:00am EST.
To view, listen to, and participate in the live webcast, please
follow the link below:
https://app.webinar.net/nwjXzxokLQl
To listen and participate via the conference call, please
dial:
North American Toll-Free: 1-888-664-6392
Local (Toronto): 416-764-8659
Confirmation Number: 97297097
Participants will be able to ask questions of Company management
during the Q&A portion of the conference call either by asking
them on the call or by submitting them using the chat function on
the webcast.
A recording of the call will be available by calling
1-888-390-0541 or 416-764-8677 and entering the encore replay entry
code 297097# until September
12th, 2022. A recording of the call will also be
available on www.covalon.com under News & Events on the
Investors tab.
Copies of Covalon's financial statements and MD&A can be
obtained on SEDAR at www.sedar.com and under Sedar Filings on the
Investors tab of Covalon's website.
About Covalon
Covalon Technologies Ltd. is a researcher, developer,
manufacturer, and marketer of patent-protected medical products
that improve patient outcomes and save lives in the areas of
advanced wound care, infection management and surgical procedures.
Covalon leverages its patented medical technology platforms and
expertise in two ways: (i) by developing products that are sold
under Covalon's name; and (ii) by developing and commercializing
medical products for other medical companies under development and
license contracts. The Company is listed on the TSX Venture
Exchange, having the symbol COV and trades on the OTQX Market under
the symbol CVALF. To learn more about Covalon, visit our website at
www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results, the
impact and timing of COVID-19 on operating activities and market
conditions, and other risks, any of which could cause
results, performance, or achievements to differ materially from the
results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific
to the Company. Investors should consult the Company's ongoing
quarterly filings for additional information on risks and
uncertainties relating to these forward-looking statements.
Investors should not place undue reliance on any forward-looking
statements. The Company assumes no obligation to update or alter
any forward-looking statements whether as a result of new
information, further events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-announces-conference-call-to-discuss-third-quarter-fiscal-2022-financial-results-301611485.html
SOURCE Covalon Technologies Ltd.